Ranbaxy has a strong R&D competence that provides a sustainable competitive advantage to the company. It has scholarly pool of about 1100 scientists, engaged in out-of-box researches. Ranbaxy spends over 7% of its sales on R&D. Licensing of once-a-day Ciprofloxacin formulation, using NDDS (Novel Drug Delivery System) on a worldwide basis, was the first international success for the company.
Ranbaxy is focused on Discovery and development of drugs on anti-infectives, urology, respiratory/ inflammatory and metabolic diseases.
Top ten molecules of the company are:
- Co-amoxiclav
- Amoxicillin
- Ciprofloxacin
- Cephalexin
- Simvastatin
- Isotretinoin
- Cefaclor
- Clarithromycin
- Cefpodoxime Proxetil
- Ketorolac Tromethamine
Corporate office:
Plot 90, Sector 32,
Gurgaon -122001 (Haryana), INDIA
Ph: +91-124-4135000
Fax: +91-124-4135001
Web site: www.ranbaxy.com
Quarterly Results of Ranbaxy
Quarterly Results (Rs.in Millions) |
|
Dec 2006(3 rd quarter) |
Sept 2006(2nd quarter) |
Dec 2005(3 rd quarter) |
Sales Turnover |
10159.8 |
11035.9 |
8820.4 |
Other Income |
294.8 |
-190.9 |
250.4 |
Total Income |
10454.6 |
10845 |
9070.8 |
Total Expenditure |
8410.9 |
9064.5 |
8248.7 |
Operating Profit |
2043.7 |
1780.5 |
822.1 |
Interest |
136 |
176 |
67.9 |
Gross Profit |
1907.7 |
1604.5 |
754.2 |
Depreciation |
254.6 |
292.1 |
269.6 |
Tax |
262.4 |
113.3 |
-4.3 |
*Source: economictimes.indiatimes.com
Quarterly Results (in %) |
|
% Change Over Sep 2006 |
% Change Over Dec 2005 |
Sales Turnover |
-7.94 |
15.19 |
Other Income |
0 |
17.73 |
Total Income |
-3.6 |
15.26 |
Total Expenditure |
-7.21 |
1.97 |
Operating Profit |
14.78 |
148.6 |
Interest |
-22.73 |
100.29 |
Gross Profit |
18.9 |
152.94 |
Depreciation |
-12.84 |
-5.56 |
Tax |
|
|
Reported PAT |
42.91 |
41.92 |
*Source: economictimes.indiatimes.com
Annual Results of Ranbaxy
Annual Unaudited Results (Rs. in Millions) |
|
(12 Months) |
(12 Months) |
% Changes |
Sales Turnover |
39,735.60 |
34,901.30 |
13.85 |
Other Income |
795.7 |
2,096.60 |
-62.05 |
Total Income |
40,531.30 |
36,997.90 |
9.55 |
Total Expenditure |
34,141.10 |
34,243.70 |
-0.3 |
Operating Profit |
6,390.20 |
2,754.20 |
132.02 |
Interest |
581 |
264.1 |
119.99 |
Gross Profit |
5,809.20 |
2,490.10 |
133.29 |
Depreciation |
1,117.60 |
1,013.30 |
10.29 |
Tax |
601.1 |
-223.4 |
-369.07 |
Reported PAT |
3,864.50 |
2,237.00 |
72.75 |
*Source: economictimes.indiatimes.com
|
